{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:09:08Z","timestamp":1790701748163,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,5,1]],"date-time":"2027-05-01T00:00:00Z","timestamp":1809129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,5,1]],"date-time":"2027-05-01T00:00:00Z","timestamp":1809129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,5]]},"DOI":"10.1016\/j.vhri.2026.102137","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:53:52Z","timestamp":1790700832000},"page":"102137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed\/Refractory Multiple Myeloma in Iran"],"prefix":"10.1016","volume":"59","author":[{"given":"Neshaut","family":"Mashreghi Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mahdi","family":"Raeis Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekoufeh","family":"Nikfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2026.102137_bib1","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41598-024-83630-x","article-title":"A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast","volume":"15","author":"Hou","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.vhri.2026.102137_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1527198","article-title":"Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021","volume":"13","author":"Zhuge","year":"2025","journal-title":"Front Public Health"},{"issue":"8","key":"10.1016\/j.vhri.2026.102137_bib3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.vhri.2026.102137_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.clml.2021.04.013","article-title":"Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the myeloma XI trial","volume":"21","author":"Bird","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.vhri.2026.102137_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1177\/1078155220934162","article-title":"Age demographics of subjects enrolled in interventional phase 3 multiple myeloma clinical trials","volume":"26","author":"Borad","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.vhri.2026.102137_bib6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vhri.2026.102137_bib7","first-page":"237","article-title":"Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma","volume":"5","author":"Fostier","year":"2012","journal-title":"Onco Targets Ther"},{"issue":"15","key":"10.1016\/j.vhri.2026.102137_bib8","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.2165\/11209010-000000000-00000","article-title":"Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma","volume":"72","author":"McCormack","year":"2012","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.vhri.2026.102137_bib9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjh.14014","article-title":"Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay","volume":"173","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.vhri.2026.102137_bib10","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.vhri.2026.102137_bib11","first-page":"1205","article-title":"Comparison of health care costs and resource utilization for commonly used proteasome inhibitor\u2013immunomodulatory drug-based triplet regimens for the management of patients with relapsed\/refractory multiple myeloma in the United States","volume":"29","author":"Sanchez","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.vhri.2026.102137_bib12","first-page":"1431","article-title":"Health care costs among patients with relapsed\/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States","volume":"30","author":"Ailawadhi","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.vhri.2026.102137_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17474086.2017.1391088","article-title":"Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States","volume":"10","author":"Jakubowiak","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.vhri.2026.102137_bib15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40258-019-00513-3","article-title":"A review of recent decision-analytic models used to evaluate the economic value of cancer treatments","volume":"17","author":"Bullement","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"10","key":"10.1016\/j.vhri.2026.102137_bib16","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (Endeavor): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vhri.2026.102137_bib17","series-title":"Sensitivity analysis: an introduction for the management scientist. International Series in Operations Research & Management Science","first-page":"27","author":"Borgonovo","year":"2017"},{"issue":"2","key":"10.1016\/j.vhri.2026.102137_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40273-019-00869-3","article-title":"One-way sensitivity analysis for probabilistic cost-effectiveness analysis: conditional expected incremental net benefit","volume":"38","author":"McCabe","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vhri.2026.102137_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1539-6924.2006.00790.x","article-title":"Direct estimation of the cost effectiveness of tornado shelters","volume":"26","author":"Simmons","year":"2006","journal-title":"Risk Anal"},{"issue":"7210","key":"10.1016\/j.vhri.2026.102137_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/bmj.319.7210.635","article-title":"Handling uncertainty in economic evaluations of healthcare interventions","volume":"319","author":"Briggs","year":"1999","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.vhri.2026.102137_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hec.4730040502","article-title":"Sensitivity analysis in economic evaluation: a review of published studies","volume":"4","author":"Briggs","year":"1995","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.vhri.2026.102137_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40273-020-00983-7","article-title":"Probabilistic one-way sensitivity analysis with multiple comparators: the conditional net benefit frontier","volume":"39","author":"McCabe","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2026.102137_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (Endeavor): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.vhri.2026.102137_bib24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/13696998.2019.1569457","article-title":"Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland","volume":"22","author":"Mankinen","year":"2019","journal-title":"J Med Econ"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:54:07Z","timestamp":1790700847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926005522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,5]]},"references-count":23,"alternative-id":["S2212109926005522"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102137","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed\/Refractory Multiple Myeloma in Iran","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"102137"}}